Nanna Therapeutics
Daniel Raines is a skilled medical chemist currently employed at Astellas Pharma since April 2024. Additionally, Daniel has been serving as a research scientist at Nanna Therapeutics since April 2018. Previously, Daniel worked as a postdoctoral research associate at the University of York from January 2015 to December 2017, where the focus was on the investigation of artificial enzymes. Daniel's academic journey began with a PhD at the University of York from September 2010 to October 2014, following the completion of a Master of Chemistry (MChem) degree in chemistry at the same university from 2006 to 2010.
Nanna Therapeutics
Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer.Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treatage-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies.Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.